Cargando…

The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis

BACKGROUND AND PURPOSE: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the prognostic and clinicopathological significance in patients with esophageal squamous cell carcinoma (ESCC) has been reported by ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yugui, Zhang, Lifei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257133/
https://www.ncbi.nlm.nih.gov/pubmed/30538564
http://dx.doi.org/10.2147/CMAR.S171035
_version_ 1783374268255436800
author Sun, Yugui
Zhang, Lifei
author_facet Sun, Yugui
Zhang, Lifei
author_sort Sun, Yugui
collection PubMed
description BACKGROUND AND PURPOSE: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the prognostic and clinicopathological significance in patients with esophageal squamous cell carcinoma (ESCC) has been reported by many studies. However, inconsistent results have been presented. The current study aimed to investigate the prognostic and clinicopathological role of NLR, PLR, and LMR in patients with ESCC by meta-analysis. METHODS: Eligible studies were identified in databases and the relationship between NLR/PLR/LMR and the prognosis or clinicopathological features in patients with ESCC was evaluated. OR or HR with 95% CI was calculated to estimate the risk or hazard association. RESULT: Twenty-six studies including 8,586 ESCC patients were included for the analysis. We found that high NLR, PLR and low LMR were associated with poor overall survival/cancer-specific survival and event-free survival and malignant phenotypes such as deeper depth of invasion (T), positive lymph node metastasis (N), and advanced TNM stage. CONCLUSION: NLR, PLR, and LMR might serve as prognostic markers in patients with ESCC.
format Online
Article
Text
id pubmed-6257133
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62571332018-12-11 The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis Sun, Yugui Zhang, Lifei Cancer Manag Res Original Research BACKGROUND AND PURPOSE: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the prognostic and clinicopathological significance in patients with esophageal squamous cell carcinoma (ESCC) has been reported by many studies. However, inconsistent results have been presented. The current study aimed to investigate the prognostic and clinicopathological role of NLR, PLR, and LMR in patients with ESCC by meta-analysis. METHODS: Eligible studies were identified in databases and the relationship between NLR/PLR/LMR and the prognosis or clinicopathological features in patients with ESCC was evaluated. OR or HR with 95% CI was calculated to estimate the risk or hazard association. RESULT: Twenty-six studies including 8,586 ESCC patients were included for the analysis. We found that high NLR, PLR and low LMR were associated with poor overall survival/cancer-specific survival and event-free survival and malignant phenotypes such as deeper depth of invasion (T), positive lymph node metastasis (N), and advanced TNM stage. CONCLUSION: NLR, PLR, and LMR might serve as prognostic markers in patients with ESCC. Dove Medical Press 2018-11-22 /pmc/articles/PMC6257133/ /pubmed/30538564 http://dx.doi.org/10.2147/CMAR.S171035 Text en © 2018 Sun and Zhang. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sun, Yugui
Zhang, Lifei
The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title_full The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title_fullStr The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title_full_unstemmed The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title_short The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
title_sort clinical use of pretreatment nlr, plr, and lmr in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257133/
https://www.ncbi.nlm.nih.gov/pubmed/30538564
http://dx.doi.org/10.2147/CMAR.S171035
work_keys_str_mv AT sunyugui theclinicaluseofpretreatmentnlrplrandlmrinpatientswithesophagealsquamouscellcarcinomaevidencefromametaanalysis
AT zhanglifei theclinicaluseofpretreatmentnlrplrandlmrinpatientswithesophagealsquamouscellcarcinomaevidencefromametaanalysis
AT sunyugui clinicaluseofpretreatmentnlrplrandlmrinpatientswithesophagealsquamouscellcarcinomaevidencefromametaanalysis
AT zhanglifei clinicaluseofpretreatmentnlrplrandlmrinpatientswithesophagealsquamouscellcarcinomaevidencefromametaanalysis